본문으로 건너뛰기
← 뒤로

A Case of Tegafur-Uracil-Induced Interstitial Lung Disease Presenting as Hypersensitivity Pneumonitis.

1/5 보강
Cureus 2026 Vol.18(2) p. e103741
Retraction 확인
출처

Taguchi M, Kiwamoto T, Kawashima K, Yoshida K, Hizawa N

📝 환자 설명용 한 줄

This report describes the case of a 77-year-old man undergoing chemotherapy for synchronous lung cancer and rectal cancer.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Taguchi M, Kiwamoto T, et al. (2026). A Case of Tegafur-Uracil-Induced Interstitial Lung Disease Presenting as Hypersensitivity Pneumonitis.. Cureus, 18(2), e103741. https://doi.org/10.7759/cureus.103741
MLA Taguchi M, et al.. "A Case of Tegafur-Uracil-Induced Interstitial Lung Disease Presenting as Hypersensitivity Pneumonitis.." Cureus, vol. 18, no. 2, 2026, pp. e103741.
PMID 41869159

Abstract

This report describes the case of a 77-year-old man undergoing chemotherapy for synchronous lung cancer and rectal cancer. After receiving tegafur-uracil (UFT) plus leucovorin in combination with bevacizumab for rectal cancer, he developed exertional dyspnea. Chest computed tomography revealed diffuse bilateral centrilobular nodules and ground-glass opacities, suggesting a hypersensitivity pneumonia (HP) pattern of drug-induced interstitial lung disease (DI-ILD), and he was therefore admitted for further evaluation and treatment. Bronchoalveolar lavage demonstrated an increased lymphocyte fraction with a decreased CD4/CD8 ratio, and a drug-induced lymphocyte stimulation test was positive only for UFT. Based on the clinical course and these findings, the patient was diagnosed with UFT-induced interstitial lung disease. His respiratory condition improved rapidly following corticosteroid therapy. DI-ILD associated with UFT is rare, and to the best of our knowledge, no previous reports have described an HP pattern on imaging. We therefore report this case with a review of the relevant literature.

같은 제1저자의 인용 많은 논문 (4)